A study published in the journal Biomedicine & Pharmacotherapy in October showed that a molecule naturally produced by the human body can help protect vision from damage caused by excess blood sugar. This finding opens new possibilities for developing strategies to prevent diabetic retinopathy.
Diabetic retinopathy is a complication affecting over 22% of diabetes patients worldwide. It occurs when high glucose levels cause inflammation and damage nerve cells and blood vessels in the retina, which can lead to irreversible vision loss.
An international study supported by FAPESP brought together scientists from the Federal University of São Paulo (Unifesp) and the State University of Paulista (Unesp) in collaboration with the Anschutz University of Colorado in the United States. The research group studied the peptide Ac2-26, which is part of an anti-inflammatory protein called Annexin A1, using experimental models that mimic the human eye.
Tests were conducted on isolated retinal cell cultures and three-dimensional structures functioning as 'mini-retinas' (organoids), both derived from patient stem cells. During the experiments, the peptide demonstrated multifaceted action: it reduced inflammation, suppressed oxidative stress, and protected mitochondrial function (cellular structures that generate energy). These actions collectively prevented the death of nerve cells exposed to high glucose levels.
Christiane Gil, head of the Department of Morphology and Genetics at the Paulista School of Medicine (EPM-Unifesp) and co-author of the article, noted: 'We were able to demonstrate a protective effect on the retina and a potentially new strategy for preventing diabetic retinopathy.' Previously, Gil's group had established the important role of Annexin A1 in regulating inflammation and changes in blood vessels and glial cells, but testing the peptide on organoids mimicking diabetic retinopathy required further investigation.
As diabetic retinopathy progresses, the toxic environment created by oxidative stress and inflammation leads to premature death of retinal nerve cells. When this initial damage intensifies, the eye attempts to adapt by forming new blood vessels haphazardly—a process known as angiogenesis. However, these structures are very fragile, easily rupture, and cause hemorrhages, which further worsens vision loss.
Rafael Andre da Silva, a researcher from the University of Colorado and the first author of the study, explained: 'The peptide inhibits pathways signaling cell death, preventing retinal nerve cells from dying, which current treatments for diabetic retinopathy cannot do. Today's available therapies act at a different stage of the disease—the stage of neovascularization [new vessel formation], and often arrive too late to protect neuronal cells. As is known, neurons do not regenerate; that is, when they die, the damage becomes permanent.'
For Natalia Vergara, director of the Eye Development and Translational Technologies Laboratory at the Anschutz University of Colorado, the main legacy of the research goes beyond simply describing the peptide's action. The most significant finding was the identification of a biological pathway capable of slowing down diabetic retinopathy and protecting neurons, which could guide the creation of new treatments in the future.
Vergara emphasized: 'Diabetic retinopathy is not just a vascular disease, as retinal nerve cells suffer even at early stages. By demonstrating that the peptide Ac2-26 helped protect these cells from the consequences of high glucose and inflammation, including mitochondrial dysfunction, we have opened the door to developing therapies that will directly target nerve tissue, which could complement current treatment methods.'
According to Vergara, collaboration was critical to the discovery. While Brazilian researchers accumulated years of experience studying Annexin A1 and the Ac2-26 peptide, the lab she directs in the US specializes in human retinal cells and retinal organoids. 'By combining this knowledge, we were able to test the peptide on human retinal models and ask new scientific questions.'
Experiments conducted with organoids allowed the laboratory to reproduce part of the cellular diversity and layered organization of the human retina, as well as the damaging environment created by diabetes. Thanks to this, the team discovered that the peptide Ac2-26 binds to a receptor on the cell called FPR2. This binding acts as a 'brake' for p38 and NOX4 molecules, which stimulate the production of free radicals. It is these radicals in excess that cause oxidative stress and damage mitochondria, the cell's power stations.
Silva explained: 'By reducing this process, Ac2-26 helps maintain cellular function and increases the survival rate of retinal nerve cells under conditions of high glucose and inflammation characteristic of diabetic retinopathy.'
The study also revealed the central role of Müller cells, structures running throughout the retina. As Silva explains, they are necessary for protecting and nourishing the eye, but they react excessively under stress. This triggers a process called 'gliosis,' which intensifies inflammation and ultimately leads to nerve cell death. Ac2-26 was able to stop this reaction by reorganizing the inflammatory environment of the mini-retina.
Gil concluded: 'Although it was already known that diabetes damages retinal nerve cells at the earliest stage of the disease, the breakthrough of our research lies in demonstrating for the first time a molecule capable of stopping this cellular self-destruction in human tissues. This will allow progress in animal and human studies for the future creation of local drugs that can be applied at the first signs of diabetic retinopathy.'
_

